Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration

[1] Rosenfeld PJ(2006)Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419-1431

[2] Brown DM(2009)Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study Ophthalmology 116 57-65.e55

[3] Heier JS(2018)2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations Ophthalmologica 239 181-193

[4] Boyer DS(2019)Anti-vascular endothelial growth factor for neovascular age-related macular degeneration Cochrane Database Syst Rev 3 Cd005139-3342

[5] Kaiser PK(2020)Trends in real-world neovascular AMD treatment outcomes in the UK Clin Ophthalmol 14 3331-146

[6] Chung CY(2018)Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors Prog Retin Eye Res 65 127-1544

[7] Kim RY(2020)To evaluate the effect of COVID-19 pandemic and national lockdown on patient care at a tertiary-care ophthalmology institute Indian J Ophthalmol 68 1540-2628

[8] Brown DM(2020)Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic Graefes Arch Clin Exp Ophthalmol 258 2621-12

[9] Michels M(2021)Intravitreal injections during COVID-19 outbreak: real-world experience from an Italian tertiary referral center Eur J Ophthalmol 31 10-454

[10] Kaiser PK(2020)National survey of Canadian Retina Society members on guidelines for ophthalmic care during the COVID-19 crisis: Canadian Retina Research Network (CR2N) COVID-19 Steering Committee analysis Can J Ophthalmol 55 452-2598

[1] Rosenfeld PJ(2006)Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419-1431

[2] Brown DM(2009)Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study Ophthalmology 116 57-65.e55

[3] Heier JS(2018)2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations Ophthalmologica 239 181-193

[4] Boyer DS(2019)Anti-vascular endothelial growth factor for neovascular age-related macular degeneration Cochrane Database Syst Rev 3 Cd005139-3342

[5] Kaiser PK(2020)Trends in real-world neovascular AMD treatment outcomes in the UK Clin Ophthalmol 14 3331-146

[6] Chung CY(2018)Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors Prog Retin Eye Res 65 127-1544

[7] Kim RY(2020)To evaluate the effect of COVID-19 pandemic and national lockdown on patient care at a tertiary-care ophthalmology institute Indian J Ophthalmol 68 1540-2628

[8] Brown DM(2020)Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic Graefes Arch Clin Exp Ophthalmol 258 2621-12

[9] Michels M(2021)Intravitreal injections during COVID-19 outbreak: real-world experience from an Italian tertiary referral center Eur J Ophthalmol 31 10-454

[10] Kaiser PK(2020)National survey of Canadian Retina Society members on guidelines for ophthalmic care during the COVID-19 crisis: Canadian Retina Research Network (CR2N) COVID-19 Steering Committee analysis Can J Ophthalmol 55 452-2598